In Brief: Guidant
This article was originally published in The Gray Sheet
Executive Summary
Guidant: Receives expanded FDA approval of its balloon dilatation catheters for use in performing angioplasty during heart attacks, the firm says in a June 5 release. The expanded labeling is based on data from the Global Use of Strategies to Open Occluded Arteries II (GUSTO IIb) sub-study which was published in the June 5 New England Journal of Medicine. The study, by Stephen Ellis, MD, Cleveland Clinic, Ohio, et al., showed that balloon angioplasty "provides a small-to-moderate, short-term clinical advantage over thromboloytic therapy" with recombinant tissue plasminogen activator...